AN2 Therapeutics, Inc.ANTXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | -175.73% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.50% | +0.98% | +1.16% | +1.46% | +1.11% |
| Weighted Average Shares Diluted Growth | +0.50% | +0.98% | +1.16% | +1.46% | +1.11% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -78.57% | +0.00% | +800.00% | -60.00% | +200.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -33.63% | -32.92% | -30.10% | -31.17% | -32.73% |
| Book Value per Share Growth | -34.69% | -34.34% | -30.81% | -32.12% | -35.89% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | -63.82% | -47.53% | -73.66% | -15.53% | +27.46% |
| SG&A Expenses Growth | -17.61% | +5.66% | +7.64% | -12.74% | -24.08% |